Corixa

Corixa Corporation was a biotechnology company focused on developing immunotherapeutic products for cancer, autoimmune diseases, and infectious diseases. The company was a pioneer in the development of vaccine adjuvants, most notably monophosphoryl lipid A (MPL), which became a critical component in several global vaccines. Corixa's lead commercial product was Bexxar, a radiopharmaceutical treatment for patients with CD20-positive follicular non-Hodgkin's lymphoma. The company built a robust portfolio through internal research and strategic acquisitions, including Coulter Pharmaceutical and Ribi ImmunoChem Research. In 2005, Corixa was acquired by GlaxoSmithKline for approximately $300 million, primarily to integrate its adjuvant technology and manufacturing expertise.